Chip stocks fall with Nvidia after data center rev disappointment
Rodney James Williams, a director at Zomedica Corp. (NYSE:ZOM), recently purchased 100,000 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The acquisition, made on March 17, 2025, was executed at a price of $0.069 per share, totaling $6,900. According to InvestingPro data, the stock’s RSI currently indicates oversold conditions, while the company maintains a strong cash position exceeding its debt obligations. Following this transaction, Williams directly owns 100,000 shares of Zomedica. Additionally, he holds 40,000 shares indirectly through an IRA managed by the Entrust Group. With an overall Financial Health score of FAIR from InvestingPro, which analyzes 13+ key financial metrics, the company shows mixed signals. Investors seeking deeper insights can access the comprehensive Pro Research Report, available exclusively with an InvestingPro subscription.
In other recent news, Zomedica Pharmaceuticals (NYSE:ZOM) Corp reported its fourth-quarter 2024 earnings, revealing a revenue of $7.9 million, which represents an 8% increase compared to the same period last year. Despite a net loss of $7.2 million, the company maintained a strong gross margin of 70.3% and ended the year with $71.4 million in cash, cash equivalents, and available securities. The company also achieved a record full-year revenue of $27.3 million for 2024. Zomedica’s strategic focus on expanding its presence in the veterinary and equine markets contributed to this growth. Additionally, the company announced its transition to the OTCQB Venture Market following a delisting from the NYSE American Exchange due to non-compliance with listing standards. While the delisting was a setback, Zomedica remains committed to exploring options to enhance its share price and aims to engage investors through monthly webinars. The company is also focusing on international expansion and plans to continue its efforts to reduce operating expenses while working towards achieving cash flow breakeven at a $50 million run rate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.